Furthermore, recent research suggests that the HGF-c-Met axis limits the efficacy of cancer immunotherapy by modulating immune cell function and the expression of programmed cell death ligand 1 (PD-L1) [6,7,8,9]. This evidence concerns the gene HGF and cancer.